BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+4.79%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$515M
AUM Growth
–
Cap. Flow
+$464M
Cap. Flow
% of AUM
90.13%
Top 10 Holdings %
Top 10 Hldgs %
87.64%
Holding
24
New
22
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Ligand Pharmaceuticals
LGND
|
$136M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$71.1M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$52.3M |
| 4 |
ARRY
Array Biopharma Inc
ARRY
|
$50.5M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
$32.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 70.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ligand Pharmaceuticals
LGND
$3.15B
| $136M | 26.3% | +3,621,665 | New | +$136M |
|
|
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
| $71.1M | 13.79% | +5,026,766 | New | +$71.1M |
|
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $52.3M | 10.14% | +5,252,561 | New | +$52.3M |
|
|
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
| $50.5M | 9.81% | +11,131,858 | New | +$50.5M |
|
|
5
Rigel Pharmaceuticals
RIGL
$697M
| $32.5M | 6.31% | +9,730,697 | New | +$32.5M |
|
6
Gyre Therapeutics
GYRE
$703M
| $26.4M | 5.11% | +6,171,669 | New | +$26.4M |
|
7
Cytokinetics
CYTK
$4.23B
| $19.9M | 3.86% | +1,718,905 | New | +$19.9M |
|
|
CASC
8
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $12.6M | 2.45% | +8,093,278 | New | +$12.6M |
|
9
Exelixis
EXEL
$10.1B
| $11.4M | 2.2% | +2,502,256 | New | +$11.4M |
|
|
QLTI
10
DELISTED
QLT Inc
QLTI
| $10.4M | 2.02% | +2,370,263 | New | +$10.4M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.51M | 1.46% | +305,786 | New | +$7.51M |
|
|
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $6.37M | 1.24% | +320,000 | New | +$6.37M |
|
|
ARQL
13
DELISTED
Arqule Inc
ARQL
| $6.11M | 1.19% | +2,632,432 | New | +$6.11M |
|
14
Cassava Sciences
SAVA
$110M
| $5.21M | 1.01% | +2,357,327 | New | +$5.21M |
|
|
AVNR
15
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $4.63M | 0.9% | +1,006,053 | New | +$4.63M |
|
|
PTN
16
DELISTED
Palatin Technologies
PTN
| $3.12M | 0.61% | +5,200,000 | New | +$3.12M |
|
17
Enanta Pharmaceuticals
ENTA
$180M
| $2.72M | 0.53% | +153,500 | New | +$2.72M |
|
|
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
| $2.61M | 0.51% | +266,445 | New | +$2.61M |
|
|
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $2.07M | 0.4% | +4,477,000 | New | +$2.07M |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $931K | 0.18% | +151,406 | New | +$931K |
|
|
PRTK
21
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $453K | 0.09% | +150,000 | New | +$453K |
|
|
GNVC
22
DELISTED
GenVec, Inc.
GNVC
| $180K | 0.03% | +486,100 | New | +$180K |
|